Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.32 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 5/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 7/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1037108 | 0.94 | REN (0.35) | RENRORC | |
| SCHEMBL1037803 | 0.89 | REN (0.38) | RENPPARGPPARA | |
| SCHEMBL1038318 | 0.87 | REN (0.37) | RENGRM5CYSLTR2CYSLTR1MAOB | |
| SCHEMBL3906171 | 0.85 | REN (0.37) | RENGRM5CYSLTR2CYSLTR1RORC | |
| SCHEMBL1040689 | 0.85 | REN (0.33) | REN | |
| SCHEMBL1040326 | 0.84 | REN (0.34) | RENGRM5 | |
| SCHEMBL3907364 | 0.84 | REN (0.37) | RENGRM5RORC | |
| SCHEMBL1037839 | 0.84 | REN (0.36) | RENGRM5CYSLTR2CYSLTR1RORC | |
| SCHEMBL3274719 | 0.83 | REN (0.36) | REN | |
| SCHEMBL3905453 | 0.82 | REN (0.37) | RENGRM5RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049514-B1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2011-01-26 | — | — | EP | disclosed |
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOS2, NOS1, NOS3 | REN 29/4885GRM5 1426/4885CYSLTR2 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.